



COPY OF PAPERS ORIGINALLY FILED



1624

TECH CENTER 1600/2900

09/972,582

October 5, 2001

Sarvajit CHAKRAVARTY

→ +

TRANSMITTAL

FORM

PTC/SB/21 (08-00)
Approved for use through 10/31/02. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number

First Named Inventor

Filing Date

		Group Art Unit	1624			
		Group Art Unit	1027			
(to be used for all correspondence after initial		ial filing)	Examiner Name	To Be Assig	ned	
Total Number Of Pages In This Submission		10	Attorney Docket No.	21900202840)2	
ENCLOSURES (check all that apply)						
Fee Transmittal Form			ignment Papers an Application)		After Allowance Communication to Group	
Fee Attached		Drawing(s)			Appeal Communication to Board of Appeals and Interferences	
Amendment / Reply		Lice	Licensing-related Papers		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
After Final		Pet	Petition		Proprietary Information	
Affidavits/declarations			ition to Convert to a visional Application		Status Letter	
Extension of Time Request		Pov Cha	ver of Attorney, Revocation inge of Correspondence Add	tress (x	Other Enclosure(s) (please identify below): Return postcard	
[Ten	minal Disclaimer			
Express Abandonment Request		Red	uest for Refund			
Information Disclosure Statement; PTO form 1449		CD.	Number of CD(s)			
Certified Copy of Priority Document(s)		Remarks				
Response to Missing Parts/ Incomplete Application						
Response to Missing Parts under 37 CFR 1.52 or 1.53						
SIGNATURE OF APPLICANT, ATTORNEY OR AGENT						
Firm Kate H. Murashige						
or	Registration No. 29,959					
Individual Name						
Signature Cale 14. Yu		una	el.			
Date May Z ^D , 2002						
CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"						

Garee A. Haney

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed

to: Assistant Commissioner for Patents, Washington, D.C. 20231, on May 20, 2002.





TECH CENTER 1600/2900

PATENT

Docket No. 219002028402

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on May 202.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Sarvajit CHAKRAVARTY et al.

Serial No.:

09/972,582

Filing Date:

October 5, 2001

For:

QUINAZOLINE DERIVATIVES AS

MEDICAMENTS

Examiner: To Be Assigned

Group Art Unit: 1624

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 09/141,916, filed August 28, 1998, now United States Patent Number 6,184,226, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.



This Information Disclosure Statement is submitted:

	With t	With the application; accordingly, no fee or separate requirements are required.				
\boxtimes	Within three months of the application filing date or before mailing of a first Office					
	Action	on the merits; accordingly, no fee or separate requirements are required.				
	After	receipt of a first Office Action on the merits but before mailing of a final Office				
	Action	Action or Notice of Allowance.				
		A fee is required. A check in the amount of * is enclosed.				
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached				
		to this submission in duplicate.				
		A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee				
		is believed to be due.				
	After	After mailing of a final Office Action or Notice of Allowance, but before payment of				
	issue fee.					
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the				
		amount of * is enclosed.				
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmitta				
		form (PTO/SB/17 is attached to this submission in duplicate.				

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to



charge the cost of such petitions and/or other fees due in connection with the filing of this document to <u>Deposit Account No. 03-1952</u> referencing <u>219002028402</u>. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: May 20, 2002

Respectfully submitted,

By: Kate H. Murashige

Registration No. 29,959

Morrison & Foerster LLP 3811 Valley Centre Drive

Suite 500

San Diego, California 92130-2332

Telephone: (858) 720-5112 Facsimile: (858) 720-5125